German Patients Face Ever-Higher Charges

21 March 1997

Millions of German patients now face higher health insurance fundpremiums in addition to the controversial higher charges for drug prescriptions and medical treatment planned by the government.

A number of leading health funds, including the major supplementary funds, have already sent proposals to their management boards to raise contribution rates. Their aim is to undermine the new mechanism planned by the government to establish a clear link between increases in premiums and patient charges.

Under the government arrangement, there will be an across-the-board increase of about 5% from July 1. If a health fund planned to increase its premium rates after March 11, the patient charges would rise by one Deutschemark for every 0.1% rise in premiums. A number of funds say they have proposed rises in premiums before March 11, including most of the white-collar funds.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight